Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track OMER with free AI briefings, catalyst countdowns, and dilution alerts.

OMER · OMEROS CORP

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$95.3M Cash on Hand
CF+ Cash Runway
18.4% Short Interest
$27.5 Analyst Target (2)
Follow OMER by email Get an email when OMER reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about OMER, unsubscribe in one click. Privacy

📣 What OMER Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Narsoplimab (OMS721)
FDA approved Dec 2025 · Yartemlea
IgA Nephropathy Phase 3 · NCT03608033 Terminated
Phenylephrine And Ketorolac Cataract Phase 4 · NCT03864133 Completed
Phenylephrine 1.0%/ Ketorolac 0.3% Pain Reduction Phase 4 · NCT04829799 Withdrawn
1% preservative-free lidocaine Pain Reduction Phase 4 · NCT04829799 Withdrawn
OMS103HP Knee Injuries Phase 3 · NCT00226772 Completed
OMS103HP-S Meniscal Tear Phase 3 · NCT01406561 Completed
Phenylephrine HCl Unilateral Cataract Extraction Phase 3 · NCT02132312 Completed
OMS302 Unilateral Cataract Extraction Phase 3 · NCT02132312 Completed
Part 2 OMS302 Intraocular Lens Replacement Phase 3 · NCT02093689 Terminated
Part 1 OMS302 Intraocular Lens Replacement Phase 3 · NCT02093689 Terminated
OMS302-PE Cataract Extraction Phase 1/2 · NCT00721695 Completed
OMS906 study drug Paroxysmal Nocturnal Hemoglobinuria Phase 2 · NCT06298955 Active not recruiting
Zaltenibart Paroxysmal Nocturnal Hemoglobinuria Phase 2 · NCT05972967 Completed
OMS643762 Huntington's Disease Phase 2 · NCT02074410 Terminated
OMS302 Mydriatic Solution Cataract Phase 2 · NCT01193127 Completed
OMS302 Anti-inflammatory Solution Cataract Phase 2 · NCT01193127 Completed

Also used in these trials (approved or third-party drugs, not OMER's own candidates): Pioglitazone, Balanced Salt.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

OMER holds $95.3M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when OMER files for a raise →

👥 Who Owns OMER

Insiders 3.3% Institutions (252 holders) 49.7% Public and other holders 47%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 5,961,792 8.01% 2026-06-30
Ingalls & Snyder LLC Institution (13F) 3,095,323 4.16% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 3,058,096 4.11% 2026-09-30
UBS Group AG Institution (13F) 2,970,107 3.99% 2026-09-30
State Street Corporation Institution (13F) 2,240,906 3.01% 2026-09-30
Geode Capital Management, LLC Institution (13F) 1,895,961 2.55% 2026-09-30
Gregory A MD Demopulos
Chairman, CEO & President, Director · +2.37M options
Insider 1,893,253 2.54% 2026-02-18
Stifel Financial Corporation Institution (13F) 1,838,138 2.47% 2026-09-30
Federated Hermes, Inc. Institution (13F) 1,034,926 1.39% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 965,745 1.30% 2026-09-30
Rock Springs Capital Management, LP Institution (13F) 847,206 1.14% 2026-09-30
Morgan Stanley Institution (13F) 804,002 1.08% 2026-09-30

Share count 74,463,571 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-28
filed 2026-10-30
Demopulos Gregory A MD
Option award (A) 500,000 – –
2026-09-23
filed 2026-09-24
Borges David J.
Sale (S) 10,000 $20.95 0
2026-09-23
filed 2026-09-24
Borges David J.
Option exercise (M) 10,000 $15.58 10,000
2026-09-23
filed 2026-09-24
Borges David J.
Option exercise (M) 10,000 – –
2026-09-22
filed 2026-09-24
Borges David J.
Option exercise (M) 5,000 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2025-05-06 Narsoplimab BLA -7.5% -6.9% -44.2%

Browse all historical PDUFA outcomes →

Get the full OMER picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OMER and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.